alt-2074
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2006 (NCT00320502)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Glutathione peroxidase 1Supplementation
GPX1 supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)CN[Se]c2ccccc21- Mol. weight
- 226.18 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297259 ↗
Also known as
- alt-2074
- alt-2074
- bxt 51072
- bxt-51072
- bxt-51072
- bxt-51072
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00491543 | Phase 2 | Jun 1, 2007 | Radiant Research, Synvista Therapeutics, Inc |
| NCT00320502 | Phase 2 | May 1, 2006 | Synvista Therapeutics, Inc, Technion University, Tel Aviv University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Synvista Therapeutics, Inc | For profit | 2 | 2 | 1 | 2006 |
| Radiant Research | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Technion University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2006 |
4 organizations
Page 1 / 1